Skip to main content

Table 1 Characteristics of patients with chronic HCV infection

From: Multicenter comparison of PEG-IFN α2a or α2b plus ribavirin for treatment-naïve HCV patient in Korean population

Variables PEG-IFN alfa-2a PEG-IFN alfa-2b P*
  (n=402, 60.8%) (n=259, 39.2%)  
Genotype 1 (n=416), n (%) 254 (61.1) 162 (38.9)  
Age, years 49 ± 11 51 ± 11 0.26
 >50 years, n (%) 121 (47.6) 83 (51.2) 0.48
Gender (male), n (%) 154 (60.6) 100 (61.7) 0.74
Weight (Kg) 67 ± 12 66 ± 11 0.93
 ≥ 75 kg, n (%) 48 (18.9) 34 (21.0) 0.62
BMI (Kg/m2) 24.3 ± 3.2 24.4 ± 3.1 0.81
WBC (/mm3) 5.5 ± 2.1 5.2 ± 1.6 0.11
Hemoglobin (g/dL) 13.9 ± 1.8 13.9 ± 1.7 0.72
Platelet (x103/mm3) 173 ± 72 167 ± 71 0.46
ALT (IU/L) 104 ± 86 94 ± 80 0.26
HCV RNA (IU/mL) 2.9×106 ± 1.1×106 4.8×106 ± 1.9×106 0.24
Fibrosis (stage), F0-2/F3-4, n (%)§ 62/43 (59.0/41.0) 18/6 (75.0/25.0) 0.17
Adherence, ≥ 80%/<80% 171/83 (67.3/32.7) 115/47(71.0/29.0) 0.45
Genotype 2 or 3 (n=235), n (%) 141 (60.0) 94 (40.0)  
Age, years 49 ± 12 51 ± 11 0.19
 >50 years, n (%) 61 (43.3) 49 (52.1) 0.19
Gender (male), n (%) 79 (56.0) 54 (57.4) 0.89
Weight (Kg) 65 ± 11 64 ± 10 0.51
 ≥ 75 kg, n (%) 25 (17.7) 11 (11.7) 0.27
BMI (Kg/m2) 23.8 ± 3.3 23.9 ± 2.7 0.98
WBC (/mm3) 5.3 ± 1.5 5.1 ± 1.8 0.46
Hemoglobin (g/dL) 14.2 ± 1.6 13.7 ± 1.5 0.06
Platelet (x103/mm3) 177 ± 62 168 ± 65 0.32
ALT (IU/L) 98 ± 88 90 ± 89 0.51
HCV RNA (IU/mL) 2.0×106 ± 1.9×106 1.9×106 ± 1.0×106 0.83
Fibrosis (stage), F0-2/F3-4, n (%)# 51/10 (83.6/16.4) 8/5 (61.5/38.5) 0.12
Adherence, ≥ 80%/<80% 107/34 (75.9/24.1) 78/16 (83.0/17.0) 0.26
Genotype others (n=10), n (%) 7(70.0) 3 (30.0)  
  1. Abbreviation: HCV, hepatitis C virus; BMI, body mass index; ALT, alanine aminotransferase; PEG-IFN, peginterferon; F0-2, no or insignificant fibrosis; F3-4, significant fibrosis or cirrhosis.
  2. mean ± standard deviation.
  3. §, # Data were available only in 129 (genotype 1) and 74 (genotype 2/3) patients who underwent liver biopsy before initiation of antiviral treatment.